The DIABLO Knockout Huh-7 Polyclonal Cells represent a CRISPR/Cas9-edited human polyclonal cell population in which the DIABLO gene has been disrupted to generate a loss-of-function model for studying apoptosis regulation. This tool is derived from the Huh-7 hepatocellular carcinoma cell line and provides a population-level knockout of the gene encoding SMAC/DIABLO, a critical mitochondrial pro-apoptotic factor. The CRISPR/Cas9 system was employed to introduce target-gene disruption, resulting in a heterogeneous mixture of edited alleles suitable for biochemical and functional analyses in apoptosis and cancer research.
The host cell line, Huh-7, is a well-differentiated hepatocellular carcinoma cell line derived from a liver tumor of human origin. These epithelial cells harbor a mutant p53 tumor suppressor, which contributes to attenuated DNA-damage-induced apoptosis and is associated with chemoresistance. Huh-7 cells are widely employed in liver cancer research as a model system to investigate oncogenic signaling, drug metabolism, and apoptotic defects. The p53-deficient background makes this line particularly valuable for elucidating p53-independent cell death pathways and for evaluating therapeutic strategies that bypass p53-mediated apoptosis.
DIABLO (SMAC) encodes a mitochondrial intermembrane space protein that promotes apoptosis by neutralizing IAP-mediated caspase inhibition. Upon apoptotic stimuli, BAX/BAK-mediated mitochondrial outer membrane permeabilization releases DIABLO along with cytochrome c into the cytosol. Cytosolic DIABLO binds to IAPs, including XIAP, cIAP1, and cIAP2, via its N-terminal IAP-binding motif, thereby disrupting IAP-caspase interactions. This allows activation of caspases such as caspase-9, -3, and -7, which execute apoptosis. Thus, DIABLO functions downstream of cytochrome c and upstream of caspase activation, serving as an antagonist of the IAP checkpoint in the intrinsic apoptotic pathway.
In the context of Huh-7 hepatocellular carcinoma cells, DIABLO knockout provides a powerful model to dissect apoptosis resistance mechanisms inherent to liver cancer. Huh-7 cells with mutant p53 exhibit defective apoptotic responses to genotoxic agents, and DIABLO loss further compromises the mitochondrial apoptotic machinery, potentially unmasking alternative death pathways or adaptive IAP upregulation. This model enables researchers to examine how tumor cells evade apoptosis through modulation of the SMAC-IAP-caspase axis and to identify dependencies that can be exploited therapeutically. Moreover, the polyclonal nature of the knockout population mimics heterogeneous tumor cell responses, making it suitable for studying emergent resistance mechanisms to IAP antagonists or BH3 mimetics.
This DIABLO knockout model is applicable to a broad range of apoptosis and drug discovery contexts. Key applications include dissecting the intrinsic apoptotic pathway, evaluating IAP inhibitors (e.g., SMAC mimetics), investigating chemoresistance in liver cancer, and analyzing mitochondrial dysfunction. Representative assays include Western blotting, co-immunoprecipitation, flow cytometry-based apoptosis detection, caspase activity assays, and subcellular fractionation. These cells serve as a versatile tool for basic mechanistic and translational research in oncology and neurodegeneration. For further details, contact Ascent Research.
